<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Checklist for routine monitoring in individuals with transfusion-dependent thalassemia (TDT)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Checklist for routine monitoring in individuals with transfusion-dependent thalassemia (TDT)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Checklist for routine monitoring in individuals with transfusion-dependent thalassemia (TDT)</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Category</td> <td class="subtitle1">Children</td> <td class="subtitle1">Adults</td> </tr> <tr> <td class="divider_bottom" rowspan="9"><strong>General health</strong></td> <td>Testing prior to transfusion and possible transplant (all done once at initial evaluation): <ul class="decimal_heading"> <li>HLA typing</li> <li>DNA mapping (alpha and beta globin genes)</li> <li>RBC phenotyping</li> </ul> </td> <td>Testing prior to transfusion and possible transplant (all done once if not already available): <ul class="decimal_heading"> <li>HLA typing</li> <li>DNA mapping (alpha and beta globin genes)</li> <li>RBC phenotyping</li> </ul> </td> </tr> <tr> <td>Assessment of iron overload: <ul class="decimal_heading"> <li>Total volume of RBCs transfused – Assess every 6 to 12 months</li> <li>Serum ferritin – Every 3 months</li> <li>Iron, TIBC, TSAT – As clinically indicated (eg, if ferritin level is higher than expected)</li> <li>Baseline liver ultrasound at the time of diagnosis, repeated twice yearly in those with severe liver disease, iron overload, or cirrhosis</li> <li>Liver iron (eg, by MRI) upon increases in ferritin or changes in clinical condition that suggest increased iron burden</li> <li>Cardiac MRI at initial evaluation and if there are significant increases in ferritin</li> </ul> </td> <td>Assessment of iron overload: <ul class="decimal_heading"> <li>Total volume of RBCs transfused – Assess every 6 to 12 months</li> <li>Serum ferritin – Every 3 months</li> <li>Iron, TIBC, TSAT – As clinically indicated (eg, if ferritin level is higher than expected)</li> <li>Liver ultrasound twice yearly in those with severe liver disease, iron overload, or cirrhosis</li> <li>Liver iron (eg, by MRI) upon increases in ferritin or changes in clinical condition that suggest increased iron burden</li> <li>Cardiac MRI if there are significant increases in ferritin</li> </ul> </td> </tr> <tr> <td>CBC, reticulocyte count, and assessment of kidney function at each visit</td> <td>CBC, reticulocyte count, and assessment of kidney function at each visit</td> </tr> <tr> <td>Chemistry panel including serum calcium every 3 months</td> <td>Chemistry panel including serum calcium every 3 to 6 months</td> </tr> <tr> <td>Urinalysis every 6 months</td> <td> </td> </tr> <tr> <td>Growth and development: <ul class="decimal_heading"> <li>Weight monthly in infants, every 3 to 4 months in older children and adolescents</li> <li>Head circumference every other month in infants</li> <li>Annual growth velocity in children</li> <li>Tanner stage every 6 months in older children and adolescents</li> </ul> </td> <td>Growth and development: <ul class="decimal_heading"> <li>Weight every 3 to 6 months</li> <li>Standing height every 3 to 6 months</li> </ul> </td> </tr> <tr> <td>Routine dental evaluation every 6 months</td> <td>Routine dental evaluation every 6 months</td> </tr> <tr> <td>Vision screening every 3 months; ophthalmology examination annually</td> <td>Routine ophthalmology examination every 6 months</td> </tr> <tr class="divider_bottom"> <td>Audiology screen annually</td> <td> </td> </tr> <tr> <td rowspan="4"><strong>Specific organ systems</strong></td> <td>Hematology: <ul class="decimal_heading"> <li>CBC at any transfusion</li> <li>Blood type and antibody screen monthly if receiving chronic transfusions</li> <li>Direct antiglobulin test (DAT; direct Coombs) as clinically indicated</li> </ul> </td> <td>Hematology: <ul class="decimal_heading"> <li>CBC at any transfusion</li> <li>Blood type and antibody screen monthly if receiving chronic transfusions</li> <li>Direct antiglobulin test (DAT; direct Coombs) as clinically indicated</li> </ul> </td> </tr> <tr> <td>Hepatology: <ul class="decimal_heading"> <li>Transaminases (AST, ALT) and bilirubin (direct and total) every 3 months</li> <li>Hepatitis A, B, and C serology and serum albumin annually</li> <li>Hepatitis B and C PCR as clinically indicated</li> <li>PT and aPTT as clinically indicated</li> </ul> </td> <td>Hepatology: <ul class="decimal_heading"> <li>Transaminases (AST, ALT) and bilirubin (direct and total) every 3 to 6 months</li> <li>Hepatitis A, B, and C serology and serum albumin annually</li> <li>Hepatitis B and C PCR as clinically indicated</li> <li>PT and aPTT as clinically indicated</li> </ul> </td> </tr> <tr> <td>Cardiopulmonary: <ul class="decimal_heading"> <li>Echocardiography to evaluate for pulmonary hypertension if chronic hemolysis and/or iron overload are present</li> </ul> </td> <td>Cardiopulmonary: <ul class="decimal_heading"> <li>Echocardiography to evaluate for pulmonary hypertension if chronic hemolysis and/or iron overload are present</li> </ul> </td> </tr> <tr> <td>Endocrinology: <ul class="decimal_heading"> <li>T3, free T4, TSH annually starting at age 5 years</li> <li>PTH, calcium, and ionized calcium annually starting at age 5 years</li> <li>Fasting glucose, HbA1c, or oral glucose tolerance test* at ages 10, 12, 14, and 16 years</li> <li>IGF-1 and IGFBP-3 as clinically indicated (for growth delay)</li> <li>LH-ICMA, FSH, and estradiol as clinically indicated (for delayed puberty in females)</li> <li>Testosterone as clinically indicated (for delayed puberty in males)</li> <li>Bone density testing annually after adolescence</li> </ul> </td> <td>Endocrinology: <ul class="decimal_heading"> <li>T3, free T4, TSH annually</li> <li>PTH, calcium, and ionized calcium annually</li> <li>Fasting glucose, HbA1c*, or oral glucose tolerance test annually</li> <li>IGF-1 and IGFBP-3 as clinically indicated (for growth delay)</li> <li>Bone density testing annually</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This is a general timetable for clinical and laboratory evaluations for individuals with transfusion-dependent thalassemia (TDT). TDT includes conditions previously referred to as thalassemia major as well as some with thalassemia intermedia; clinical judgment is used to determine the appropriate interval for all testing and the specific testing and timetable in thalassemia intermedia phenotypes. Evaluations for delayed puberty are generally done for girls at age 12 years and for boys at age 14 years. Refer to UpToDate for additional discussions of thalassemia management.</div><div class="graphic_footnotes"><p>HLA: human leukocyte antigen; DNA: deoxyribonucleic acid; RBC: red blood cell; TIBC: total iron binding capacity; TSAT: transferrin saturation; MRI: magnetic resonance imaging; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PCR: polymerase chain reaction; PT: prothrombin time; aPTT: activated partial thromboplastin time; TSH: thyroid-stimulating hormone; PTH: parathyroid hormone; HbA1c: glycosylated hemoglobin; IGF-1: insulin-like growth factor-1; IGFBP-3: IGF binding protein 3; LH-ICMA: luteinizing hormone-immunochemiluminometric assay; FSH: follicle-stimulating hormone.</p>
* Chronic hemolysis and transfused RBCs both can artifactually lower the HbA1c and provide misleading information regarding glucose regulation, especially if used as a one-time isolated test. For diabetes screening, fasting blood glucose and an oral glucose tolerance test should be included in the diagnostic thinking. For individuals with steady state transfusion requirements and clinical stability, the HbA1c may be useful to follow as a means of monitoring changes from their baseline (using their prior values as a reference for detecting changes over time).</div><div class="graphic_reference">Modified with permission from: UCSF Benioff Children's Hospital Oakland, Northern California Comprehensive Thalassemia Center. Treating Thalassemia: Checklist. Available at: <a href="https://thalassemia.com/treatment-timetable.aspx" target="_blank">https://thalassemia.com/treatment-timetable.aspx</a> (Accessed on September 27, 2018). Copyright © 2017 Children's Hospital &amp; Research Center Oakland.</div><div id="graphicVersion">Graphic 114017 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
